Johan Björklund1, Yasin Folkvaljon2, Alexander Cole3, Stefan Carlsson4, David Robinson5,6, Stacy Loeb7, Pär Stattin6,8, Olof Akre1,9. 1. Department of Urology, Karolinska University Hospital, Solna, Sweden. 2. Regional Cancer Centre, Uppsala University Hospital, Uppsala, Sweden. 3. Division of Urologic Surgery, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA. 4. Section of Urology, Department of Molecular Medicine and Surgery, Karolinska Institutet, Stockholm, Sweden. 5. Department of Urology, Ryhov County Hospital, Jönköping, Sweden. 6. Department of Surgery and Perioperative Sciences, Urology and Andrology, Umeå University Hospital, Umeå, Sweden. 7. Department of Urology Population Health, the Laura and Isaac Perlmutter Cancer Center, New York University, New York, NY, USA. 8. Department of Surgical Sciences, Uppsala University, Uppsala, Sweden. 9. Clinical Epidemiology Unit, Department of Medicine Solna, Karolinska Institutet, Stockholm, Sweden.
Abstract
OBJECTIVE: To assess 90-day postoperative mortality after robot-assisted laparoscopic radical prostatectomy (RARP) and retropubic radical prostatectomy (RRP) using nationwide population-based registry data. PATIENTS AND METHODS: We conducted a cohort study using the National Prostate Cancer Register of Sweden, including 22 344 men with localized prostate cancer of clinical stage T1-T3, whose prostate-specific antigen levels were <50 μg/mL and who had undergone primary radical prostatectomy in the period 1998-2012. Vital status was ascertained through the Total Population Register. The rates for 90-day postoperative mortality were analysed using logistic regression analysis, and comparisons of 90-day mortality with the background population were made using standardized mortality ratios (SMRs). RESULTS: Of the 14 820 men who underwent RRP, 29 (0.20%) died, and of the 7 524 men who underwent RARP, 10 (0.13%) died. Mortality in the cohort during the 90-day postoperative period was lower than in an age-matched background population: SMR 0.57 (95% confidence interval [CI] 0.39-0.75). There was no statistically significant difference in 90-day mortality according to surgical method: RARP vs RRP odds ratio (OR) 1.14; 95% CI 0.46-2.81. Postoperative 90-day mortality decreased over time: 2008-2012 vs 1998-2007 OR 0.44; 95% CI 0.21-0.95, mainly because of lower mortality after RARP. CONCLUSION: The 90-day postoperative mortality rates were low after RARP and RRP and there was no statistically significant difference between the methods. Given the long life expectancy among men with low- and intermediate-risk prostate cancer, very low postoperative mortality is a prerequisite for RP, which was fulfilled by both RRP and RARP. The selection of healthy men for RP is highlighted by the lower 90-day mortality after RP compared with the background population.
OBJECTIVE: To assess 90-day postoperative mortality after robot-assisted laparoscopic radical prostatectomy (RARP) and retropubic radical prostatectomy (RRP) using nationwide population-based registry data. PATIENTS AND METHODS: We conducted a cohort study using the National Prostate Cancer Register of Sweden, including 22 344 men with localized prostate cancer of clinical stage T1-T3, whose prostate-specific antigen levels were <50 μg/mL and who had undergone primary radical prostatectomy in the period 1998-2012. Vital status was ascertained through the Total Population Register. The rates for 90-day postoperative mortality were analysed using logistic regression analysis, and comparisons of 90-day mortality with the background population were made using standardized mortality ratios (SMRs). RESULTS: Of the 14 820 men who underwent RRP, 29 (0.20%) died, and of the 7 524 men who underwent RARP, 10 (0.13%) died. Mortality in the cohort during the 90-day postoperative period was lower than in an age-matched background population: SMR 0.57 (95% confidence interval [CI] 0.39-0.75). There was no statistically significant difference in 90-day mortality according to surgical method: RARP vs RRP odds ratio (OR) 1.14; 95% CI 0.46-2.81. Postoperative 90-day mortality decreased over time: 2008-2012 vs 1998-2007 OR 0.44; 95% CI 0.21-0.95, mainly because of lower mortality after RARP. CONCLUSION: The 90-day postoperative mortality rates were low after RARP and RRP and there was no statistically significant difference between the methods. Given the long life expectancy among men with low- and intermediate-risk prostate cancer, very low postoperative mortality is a prerequisite for RP, which was fulfilled by both RRP and RARP. The selection of healthy men for RP is highlighted by the lower 90-day mortality after RP compared with the background population.
Authors: Quoc-Dien Trinh; Anders Bjartell; Stephen J Freedland; Brent K Hollenbeck; Jim C Hu; Shahrokh F Shariat; Maxine Sun; Andrew J Vickers Journal: Eur Urol Date: 2013-04-19 Impact factor: 20.096
Authors: Quoc-Dien Trinh; Jesse Sammon; Maxine Sun; Praful Ravi; Khurshid R Ghani; Marco Bianchi; Wooju Jeong; Shahrokh F Shariat; Jens Hansen; Jan Schmitges; Claudio Jeldres; Craig G Rogers; James O Peabody; Francesco Montorsi; Mani Menon; Pierre I Karakiewicz Journal: Eur Urol Date: 2011-12-22 Impact factor: 20.096
Authors: Michael Froehner; Vladimir Novotny; Rainer Koch; Steffen Leike; Lars Twelker; Manfred P Wirth Journal: Urol Int Date: 2013-03-06 Impact factor: 2.089
Authors: Mieke Van Hemelrijck; Annette Wigertz; Fredrik Sandin; Hans Garmo; Karin Hellström; Per Fransson; Anders Widmark; Mats Lambe; Jan Adolfsson; Eberhard Varenhorst; Jan-Erik Johansson; Pär Stattin Journal: Int J Epidemiol Date: 2012-05-04 Impact factor: 7.196
Authors: Anna Wallerstedt; Stavros I Tyritzis; Thordis Thorsteinsdottir; Stefan Carlsson; Johan Stranne; Ove Gustafsson; Jonas Hugosson; Anders Bjartell; Ulrica Wilderäng; N Peter Wiklund; Gunnar Steineck; Eva Haglind Journal: Eur Urol Date: 2014-10-11 Impact factor: 20.096